Medtronic plc: directors' dealings · United States · SEC (Form 4)

About Medtronic plc

Medtronic plc is one of the world’s leading medical technology companies and is listed on the NYSE in the United States under the ticker MDT. For French, Belgian, and Swiss investors, it typically fits the profile of a large-cap defensive healthcare name with exposure to long-duration structural drivers such as aging populations, chronic disease prevalence, and the shift toward less invasive procedures. Medtronic traces its origins to a small electrical repair business founded in 1949 in Minneapolis. Today, its operational headquarters remains in Minneapolis, Minnesota, United States, reinforcing its identity as a classic U.S. healthcare industrial champion with a global commercial footprint. ([medtronic.com](https://www.medtronic.com/en-us/our-company/key-facts.html?utm_source=openai)) The company’s business model spans several core medical device franchises, including cardiovascular solutions, cardiac rhythm management, structural heart therapies, vascular therapies, surgical and robotics-enabled care, neuromodulation, spine, and diabetes management. Its product set includes transcatheter aortic valve replacement systems (TAVR), pulsed field ablation (PFA) technologies, pacemakers and implantable cardiac devices, glucose monitoring and insulin delivery systems, as well as surgical instruments and related hospital technologies. This breadth gives Medtronic scale and resilience, but it also means the company must continuously invest in R&D and navigate stringent regulatory, reimbursement, and clinical evidence requirements. ([news.medtronic.com](https://news.medtronic.com/2025-05-21-Medtronic-reports-strong-finish-to-its-fiscal-year-with-its-fourth-quarter-financial-results-announces-dividend-increase?utm_source=openai)) In competitive terms, Medtronic remains a global benchmark in medtech, with a broad installed base across hospitals and physicians, and a meaningful position in both developed and emerging markets. Its scale, clinical relationships, and diversified portfolio are key advantages versus peers such as Boston Scientific, Abbott, and Johnson & Johnson’s medical device businesses. Recent management commentary has emphasized growth engines such as PFA, TAVR, neuromodulation, and spine, which suggests a deliberate shift toward higher-growth and higher-margin categories. ([news.medtronic.com](https://news.medtronic.com/2025-05-21-Medtronic-reports-strong-finish-to-its-fiscal-year-with-its-fourth-quarter-financial-results-announces-dividend-increase?utm_source=openai)) The most important recent strategic development came in May 2025, when Medtronic announced its intent to separate its Diabetes business into a new standalone company, later named MiniMed in June 2025. Management framed the move as a portfolio simplification step that would sharpen Medtronic’s focus on its highest-value franchises while allowing the diabetes unit to pursue its own growth path. Medtronic also reported solid fiscal 2025 results and increased its dividend, which underscores continued cash generation and shareholder-return discipline. ([news.medtronic.com](https://news.medtronic.com/2025-05-21-Medtronic-announces-intent-to-separate-Diabetes-business?utm_source=openai))